|
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma Clinical research trials and A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma. A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma clinical trial. Participants frequently get the best healthcare available for their A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma  A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To determine the safety and tolerance of interleukin-4 (IL-4) in patients with AIDS-related Kaposi's sarcoma. To determine the effects of IL-4 on tumor growth in patients with AIDS-related Kaposi's sarcoma. IL-4 exhibits a variety of beneficial effects on the immune system and is a potent inhibitor of Kaposi's sarcoma cells in vitro.
Details: IL-4 exhibits a variety of beneficial effects on the immune system and is a potent inhibitor of Kaposi's sarcoma cells in vitro. Patients are stratified into two groups according to CD4 count (less than 100 cells/mm3 and greater than or equal to 100 cells/mm3) and are enrolled in cohorts of four patients at each of four dose levels of IL-4 per stratum. Within each stratum, if patients at a given dose level have received at least 2 weeks of study therapy and no more than two patients experienced grade 3 or 4 drug-related toxicity, dose escalation in subsequent patients may begin. The MTD is defined as the dose at which 50 percent of patients develop grade 3 or worse toxicity. Patients with CD4 count less than 500 cells/mm3 (per 12/30/94 amendment) must be on antiretroviral therapy during study treatment. PER AMENDMENT 11/20/95: Group I - enrollment is closed, the objective has been defined. Group II - patients must have CD4 cells greater than or equal to 100/mm3 and less than 500/mm3. PER AMENDMENT 11/20/95: All patients will receive antiretroviral therapy.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Required: - Antiretroviral therapy during study treatment only in patients with CD4 count < 500 cells/mm3 (per 12/30/94 amendment). Allowed: - G-CSF for a second occurrence of grade 3 or 4 neutropenia (per 12/30/94 amendment). - Nonsteroidal anti-inflammatory agents including acetaminophen for drug-related fevers. - Systemic steroids for no more than 1 week in any 30-day period. - PCP prophylaxis with TMP/SMX, dapsone, or inhaled pentamidine, if patient has a history of PCP or a CD4 count < 250 cells/mm3. Allowed only in patients with CD4 count < 100 cells/mm3: - Maintenance doses of ganciclovir, pyrimethamine/sulfa and TMP/SMX for stable, well-controlled opportunistic infections. - Non-myelosuppressive treatment IND medications. Prior Medication: Required: PER AMENDMENT 11/20/95: - Stable dose of antiretroviral therapy required for at least 21 days prior to study entry for all patients. (Changed from - Stable dose of antiretroviral therapy for at least 21 days prior to study entry in patients with CD4 count < 500 cells/mm3 (per 12/30/94 amendment). Patients must have: - AIDS-related Kaposi's sarcoma. - PER AMENDMENT 11/20/95: CD4 lymphocyte count >= 100 but < 500 cells/mm3. (Changed from - HIV infection.) - PER AMENDMENT 11/20/95: All Patients will receive antiretroviral therapy. (Changed from - Current antiretroviral therapy IF CD4 count < 500 cells/mm3 (per 12/30/94 amendment).) - No active opportunistic infections requiring induction therapy. - Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Other active malignancies (except basal cell carcinoma of the skin and in situ cervical cancer). - Alteration in mental status that may prevent compliance. - Cardiac functional capacity of Class II or worse OR regional wall abnormalities or abnormal ejection fraction on two-dimensional echocardiogram, if performed. Concurrent Medication: Excluded: - Chemotherapy, interferons, or immune modulators for Kaposi's sarcoma. - Myelosuppressive agents such as induction doses of ganciclovir, Fansidar (pyrimethamine/sulfadoxine), or any other investigational drugs (with the exception of non-myelosuppressive treatment IND medications in specific patients). - GM-CSF or erythropoietin (except for a second grade 3/4 neutropenia or anemia). - G-CSF. Patients with the following prior conditions are excluded: - History of myocardial infarction or significant arrhythmias. - History of symptomatic hypoglycemia. Prior Medication: Excluded: - Systemic therapy (including chemotherapy, interferons, and immune modulators) for Kaposi's sarcoma within 4 weeks prior to study entry.
Total Enrollment: 48
Location and Contact Information:
Overall Study Official:
MilesS, Study Chair,
Beth Israel Deaconess - West Campus
Boston, Massachusetts, 02215
United States
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, 02114
United States
UCLA CARE Ctr
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: ACTG 224;
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000769
Other Hiv Infections Studies:
1. Comparison of Liposomal Doxorubicin Used Alone or in Combination with Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients with AIDS
2. Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients with AIDS-Related Kaposi's Sarcoma
3. Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
4. A Study of Targretin Capsules in Patients with AIDS-Related Kaposi's Sarcoma
5. A Study of Tecogalan Sodium
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
|
|
|
|
|
|
|
|
